INSY - INSYS Therapeutics, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD
0.8215
-0.0485 (-5.57%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close0.8700
Open0.8620
Bid0.0000 x 800
Ask0.0000 x 2200
Day's range0.7901 - 0.8800
52-week range0.7901 - 11.6500
Volume882,133
Avg. volume1,157,433
Market cap62.368M
Beta (3Y monthly)3.03
PE ratio (TTM)N/A
EPS (TTM)-3.0710
Earnings date6 Aug 2019 - 12 Aug 2019
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.00
Trade prices are not sourced from all markets
  • Why Insys Therapeutics Fell More than 70% Yesterday
    Market Realist10 days ago

    Why Insys Therapeutics Fell More than 70% Yesterday

    Why Insys Therapeutics Fell More than 70% YesterdayLiquidity positionIn its first-quarter earnings press release, which it published on May 10, Insys Therapeutics (INSY) highlighted the possibility of its being unable to continue as a going concern.

  • Why Insys Therapeutics Stock Is Crashing Today
    Motley Fool11 days ago

    Why Insys Therapeutics Stock Is Crashing Today

    The biotech raised the possibility of filing for bankruptcy in its latest earnings report.

  • Drugmaker Insys shares tank after saying opioid lawsuits may force it into bankruptcy
    CNBC11 days ago

    Drugmaker Insys shares tank after saying opioid lawsuits may force it into bankruptcy

    Insys Therapeutics shares tanked Monday morning after the company said it may have to file for bankruptcy because it can't afford legal costs related to a Department of Justice investigation into the company's sales practices of one of its popular opioids.

  • Opioid Maker Insys Plunges on Warning of Possible Bankruptcy
    Bloomberg11 days ago

    Opioid Maker Insys Plunges on Warning of Possible Bankruptcy

    “These factors raise substantial doubt about the company’s ability to continue as a going concern,” Insys said in a statement. Insys said last year Kapoor’s defense alone had cost the company $28 million so far.

  • MarketWatch11 days ago

    Insys stock plunges 70% after Friday disclosure of company's woes

    Shares of Insys Therapeutics Inc. plunged 70% Monday morning, a fall sparked by the biotech's Friday disclosure that mounting legal expenses and declines in the market for fast-acting fentanyl could lead it to file for bankruptcy. Insys said on Friday it was uncertain of its ability to complete a final settlement with the U.S. Justice Department to resolve an investigation into sales practices related to its fentanyl spray Subsys -- Insys reached a deal last August to pay at least $150 million to settle claims that it paid doctors kickbacks to prescribe the drug. The company also disclosed that it had just $87.6 million in cash, cash equivalents and investments at the end of March and expected continued negative cash flows from its operations. "These factors raise substantial doubt about the company's ability to continue as a going concern within one year of the issuance date of the unaudited condensed consolidated financial statements," the company said in a statement Friday. "If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our audited consolidated financial statements, and it is likely that investors will lose all or a part of their investment." Insys is also looking at a way to sell or license its assets. If it can't find a way to do that, or if the company is unable to reach an agreement with the Justice Department, its "liquidity, financial condition and business prospects will be materially and adversely affected. Accordingly, it may be necessary for the company to file a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in order to implement a restructuring," Insys said. Earlier this month, a federal jury in Boston convicted five former executives and managers, including co-founder John Kapoor, of engaging in a racketeering conspiracy to bribe doctors to prescribe Subsys in order to boost profits. The company's first-quarter revenue fell to $7.63 million from $23.91 million, while net loss widened to $123.8 million after a loss of $20.37 million a year ago. The beleaguered biotech reported an adjusted loss of 55 cents a share on Friday, missing FactSet analysts' prediction of a loss of 22 cents. Shares of Insys have fallen 69% so far this year, while the S&P 500 has gained 13%.

  • Investing $1,000 Into This Marijuana Stock in 2016 Would Leave You With Pennies on the Dollar Today
    Motley Fool11 days ago

    Investing $1,000 Into This Marijuana Stock in 2016 Would Leave You With Pennies on the Dollar Today

    This once-promising pot stock may not survive the year.

  • Insys says it may be forced to file for bankruptcy due to litigation cash crunch
    Reuters13 days ago

    Insys says it may be forced to file for bankruptcy due to litigation cash crunch

    Insys, which has been exploring strategic options and is in talks to divest its opioid product Subsys, said it was likely that investors will lose all or a part of their investments if the company is not able to sell its assets at the value they are booked in its audited financial statements. Last August, Insys reached a tentative deal to pay at least $150 million to resolve a Department of Justice investigation into claims that the drugmaker paid doctors kickbacks to prescribe Subsys, an under-the-tongue spray that contains fentanyl, an opioid 100 times stronger than morphine.

  • Insys Therapeutics (INSY) Reports Q1 Loss, Lags Revenue Estimates
    Zacks13 days ago

    Insys Therapeutics (INSY) Reports Q1 Loss, Lags Revenue Estimates

    Insys Therapeutics (INSY) delivered earnings and revenue surprises of -323.08% and -48.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press13 days ago

    Insys Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the Chandler, Arizona-based company said it had a loss of $1.66. Losses, adjusted for one-time gains and costs, were 55 cents per share. The specialty pharmaceutical company posted ...

  • John Kapoor: Insys founder guilty of bribery in landmark US opioid case
    Sky News21 days ago

    John Kapoor: Insys founder guilty of bribery in landmark US opioid case

    The founder of a multi-billion dollar drug company has been convicted of bribing doctors to prescribe its highly addictive fentanyl spray to patients who did not need it. Extreme tactics, including using a sales representative to give one medic a lap dance, were used by Insys Therapeutics to boost sales of its powerful painkiller Subsys. John Kapoor and four other former employees are now facing up to 20 years in prison on the racketeering conspiracy charges.

  • Insys founder convicted of bribing doctors to push highly addictive fentanyl spray
    MarketWatch21 days ago

    Insys founder convicted of bribing doctors to push highly addictive fentanyl spray

    A pharmaceutical company founder accused of paying doctors millions in bribes to prescribe a highly addictive fentanyl spray was convicted Thursday in a case that exposed such marketing tactics as using a stripper-turned-sales-rep to give a physician a lap dance.

  • Founder, execs of drug company guilty in conspiracy that fed opioid crisis
    Reuters21 days ago

    Founder, execs of drug company guilty in conspiracy that fed opioid crisis

    The founder of Insys Therapeutics Inc on Thursday became the highest-ranking pharmaceutical executive to be convicted in a case tied to the U.S. opioid crisis, when he and four colleagues were found guilty of participating in a scheme to bribe doctors to prescribe an addictive painkiller. A federal jury in Boston found John Kapoor, the drugmaker's former chairman, and his co-defendants guilty of racketeering conspiracy for engaging in a scheme that also misled insurers into paying for the drug. Kapoor's 2017 arrest came on the same day U.S. President Donald Trump declared the epidemic that has caused tens of thousands of overdose deaths annually a public health emergency.

  • Bloomberg21 days ago

    Insys’s John Kapoor Is First CEO Convicted of Opioid Racketeering

    Federal jurors in Boston found that Kapoor conspired with four other executives to bribe doctors to pump up sales of Subsys and duped insurers into covering shady prescriptions. Former vice president Michael Gurry, ex-national sales director Richard Simon, former regional sales director Joseph Rowan, and one-time stripper turned Insys sales manager Sunrise Lee were also found guilty.

  • Founder, executives of drug company guilty in conspiracy that fed opioid crisis
    Reuters21 days ago

    Founder, executives of drug company guilty in conspiracy that fed opioid crisis

    The founder of Insys Therapeutics Inc on Thursday became the highest-ranking drugmaker executive convicted in a case tied to the U.S. opioid crisis, when he and four colleagues were found guilty of bribing doctors to prescribe an addictive painkiller, helping drive the epidemic. A federal jury in Boston found John Kapoor, 75, the drugmaker's former chairman, and his co-defendants guilty of racketeering conspiracy for a scheme that also misled insurers into paying for the drug. Kapoor's 2017 arrest came on the same day U.S. President Donald Trump declared the epidemic that has caused tens of thousands of overdose deaths annually a public health emergency.

  • Ups and Downs in the Cannabis Space Last Week
    Market Realist25 days ago

    Ups and Downs in the Cannabis Space Last Week

    Cannabis Updates: Price Action, Ratings, and MoreCannabis spaceThe cannabis space was mostly positive last week. The Horizons Marijuana Life Sciences ETF (HMMJ) and the ETFMG Alternate Harvest ETF (MJ) gained 5.2% and 4.2%, respectively, while the

  • Cannabis Updates: New Listings, Price Action, and Ratings
    Market Realistlast month

    Cannabis Updates: New Listings, Price Action, and Ratings

    Cannabis Updates: New Listings, Price Action, and RatingsCannabis updateThe cannabis sector showed some weakness last week, and the Horizons Marijuana Life Sciences ETF (HMMJ) lost 3.0% while the ETFMG Alternate Harvest ETF (MJ) lost 3.4%.

  • 3 Marijuana Stocks to Avoid Like the Plague in April
    Motley Fool2 months ago

    3 Marijuana Stocks to Avoid Like the Plague in April

    Despite a blazing hot start to the year, these pot stocks look to be buzzkills.

  • Reuters2 months ago

    Drug company founder, execs exploited patients to sell opioid: U.S. prosecutor

    The founder of Insys Therapeutics Inc put profits over patient safety by bribing doctors to prescribe an addictive fentanyl spray, fuelling the U.S. opioid epidemic, a federal prosecutor said on Thursday at the end of a landmark trial. John Kapoor, the drugmaker's former chairman, and four colleagues are the first executives of a painkiller manufacturer to face trial for conduct that authorities say was tied to a drug abuse epidemic that kills tens of thousands of Americans each year. Kapoor was arrested in 2017 on the same day U.S. President Donald Trump declared the opioid crisis a public health emergency.

  • These Worst-Performing Pot Stocks Fell at Least 20% in March
    Motley Fool2 months ago

    These Worst-Performing Pot Stocks Fell at Least 20% in March

    There are some very familiar marijuana stocks among this bunch of losers.

  • Implied Volatility Surging for INSYS Therapeutics (INSY) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for INSYS Therapeutics (INSY) Stock Options

    Investors need to pay close attention to INSYS Therapeutics (INSY) stock based on the movements in the options market lately.

  • Insys Therapeutics (INSY) Outpaces Stock Market Gains: What You Should Know
    Zacks2 months ago

    Insys Therapeutics (INSY) Outpaces Stock Market Gains: What You Should Know

    Insys Therapeutics (INSY) closed the most recent trading day at $4.62, moving +1.99% from the previous trading session.

  • 3 Pot Stocks With Skyrocketing Short Interest
    Motley Fool2 months ago

    3 Pot Stocks With Skyrocketing Short Interest

    Pessimists are coming out of the woodwork as the green rush takes shape.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes